Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 687-692

  Wagenblast, Jens ^a   Hambek, Markus ^a   Baghi, Mehran ^a   Knecht, Rainald ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bortezomib; EGFR; Epidermal growth factor receptor; Head and neck squamous cell carcinoma cell lines

Indexed keywords

BORTEZOMIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PYRAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 42549144511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J and Whelan S: Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18(6B): 4779-4786, 1998.
2. Tumino R and Vicario G: Head and neck cancers: oral cavity, pharynx, and larynx. Epidemiol Prev 28: 28-33, 2004.
3. Bhurgri Y, Bhurgri A, Usman A, Pervez S, Kayani N, Bashir I, Ahmed R and Hasan SH: Epidemiological review of head and neck cancers in Karachi. Asian Pac J Cancer Prev 7: 195-200, 2006.
4. Baghi M, Hambek M, May A, Radeloff A, Gstoettner W and Knecht R: Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Anticancer Res 26: 559-563, 2006.
5. Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W and Knecht R: A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 26: 585-590, 2006.
6. Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H and Knecht R: Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck 29: 244-248, 2007.
7. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177, 2007.
8. Knecht R, Peters S, Hambek M, Solbach C, Baghi M and Gstottner W: EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Adv Otorhinolaryngol 62: 81-91, 2005.
9. Vermorken JB: Standard cisplatin/infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971). J Clin Oncol 22: ASCO Annual Meeting Proceedings (Post-Meeting Edition) No 14S (July 15 Supplement) 5508, 2004.
10. Tishler RB: A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol 22: ASCO Annual Meeting Proceedings (Post-Meeting Edition) No 14S (July 15 Supplement) 5548, 2004.
11. Knecht R: TPF induction chemotherapy followed by concurrent radiochemotherapy in the first line therapy of advanced carcinomas of the larynx and pharynx (phase IIb trial). J Clin Oncol 24: ASCO Annual Meeting Proceedings Part I, No 18S (June 20 Supplement) 5562, 2006.
12. Remenar E: A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971. J Clin Oncol 24: ASCO Annual Meeting Proceedings Part I, No 18S (June 20 Supplement) 5516, 2006.
13. An J, Sun YP, Adams J, Fisher M, Belldegrun A and Rettig MB: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9: 4537-4545, 2003.
14. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F and Anderson KC: Bortezomib as an antitumor agent. Curr Pharm Biotechnol 7: 441-448, 2006.
15. Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40: 2217-2229, 2004.
16. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H and Knecht R: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol, 2007 (ahead of print).
17. Milano A, Iaffaioli RV and Caponigro F: The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 43: 1125-1133, 2007.
18. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa J P, Lee JJ and Mao L: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170, 2007.
19. Ford AC and Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25: 67-73, 2003.
20. Khalil MY, Grandis JR and Shin DM: Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 3: 367-380, 2003.
21. Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
22. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N and Ichihara A: Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 51: 6677-6685, 1991.
23. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A and Albanell J: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5: 665-675, 2006.
24. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
25. An J, Sun Y, Fisher M and Rettig MB: Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 3: 727-736, 2004.
26. Marshall CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
27. Thompson JE and Thompson CB: Putting the rap on Akt. J Clin Oncol 22: 4217-4226, 2004.
28. Lorch JH, Thomas TO and Schmoll HJ: Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67: 727-734, 2007.
29. An J and Rettig MB: Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6: 61-69, 2007.